Alfacell Selects TS Communications and Feinstein Kean Healthcare for Comprehensive Integrated Communications.

BLOOMFIELD, N.J. -- Alfacell Corporation (Nasdaq: ACEL) today announced that it has engaged TS Communications Group (TSCG) and Feinstein Kean Healthcare (FKH) to integrate, enhance and accelerate the company's core investor relations and marketing communications efforts. The well-integrated, full-service TSCG/FKH team will focus on strategic and tactical support of ONCONASE(R) (ranpirnase), the company's lead drug candidate currently being evaluated in a Phase IIIb registration trial for the treatment of unresectable malignant mesothelimona (UMM) and a Phase I / II dose ranging study in non-small cell lung cancer in partnership with US Oncology. The company's portfolio of other novel ribonuclease (RNase)-derived therapeutics for cancer and other life-threatening diseases will also be supported.

Alfacell surveyed and met with several practitioners before selecting TSCG/FKH based on the team's extensive scientific and clinical experience, unique knowledge of the competitive landscape for therapeutic oncology products, and expertise in corporate and brand messaging. The senior team dedicated to supporting Alfacell will leverage these advantages as part of a comprehensive, targeted outreach program to its expansive network of financial and media contacts. The primary objective is to increase Alfacell's public presence by highlighting its well-validated technology platform, recent achievements and future prospects, as the company moves ONCONASE toward commercialization and continues to build its proprietary RNase drug discovery program.

Andrew Aromando, Senior Vice President, Commercial Development and Operations at Alfacell, stated, "We look forward to working with TSCG/FKH as we enter this critical phase of the company's evolution. With their unmatched experience in life sciences and biotech, oncology focus and expertise, and proven track record of excellence in investor, public, and media relations for late-stage development companies, TSCG/FKH is an ideal partner for us."

About Alfacell Corporation

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. For more information, please visit www.alfacell.com.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.